中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
12期
1485-1487,1490
,共4页
谭小碧%朱冬林%彭彬%贾守洪
譚小碧%硃鼕林%彭彬%賈守洪
담소벽%주동림%팽빈%가수홍
免疫增强剂%甘露聚糖肽%胸腺五肽%胸腺肽α1%术后感染
免疫增彊劑%甘露聚糖肽%胸腺五肽%胸腺肽α1%術後感染
면역증강제%감로취당태%흉선오태%흉선태α1%술후감염
Immunotherapy agents%Mannatide Injection%Thymopentin%Thymosin%Infection
目的：比较3种常用免疫增强剂联合抗生素预防老年恶性肿瘤术后感染的有效性及经济性。方法：纳入外科480例老年恶性肿瘤患者，并随机分为甘露聚糖肽注射液组、胸腺五肽组、胸腺肽α1组和空白组各120例，均行外科肿瘤根治性手术。三个治疗组术前3天至术后一周应用免疫增强剂，给药方法为甘露聚糖肽注射液10～20mg/d，胸腺五肽2ml/d，胸腺肽α13.2mg/周，空白组则不予应用免疫增强剂，术后均选用抗生素滴注，观察两组的呼吸道、泌尿系统、切口感染及其他感染情况，并对4种药物的治疗方案行经济学评价。结果：四组肿瘤患者呼吸道感染发生率分别为2.5%、3.34%、3.34%，14.16%；泌尿系统感染发生率分别为3.34%，6.67%，5.83%，15%；切口感染发生率分别为2.5%，18.35%，17.5%，15%；总感染发生率分别为15%，19.16%，18.33%，48.33%，免疫增强组术后感染的发生率明显低于空白组，其中甘露聚糖肽组预防切口感染率优势更佳，且具有统计学差异（P＜0.05），甘露聚糖肽成本-效益是免疫增强剂中最佳。结论：免疫增强剂能降低老年恶性肿瘤患者术后感染发生率，但上述三种免疫增强剂在降低总感染发生率上不具有统计学差异，甘露聚糖肽在降低切口感染方面可能优于其他2种免疫增强剂，药物经济学分析甘露聚糖肽更为经济。
目的：比較3種常用免疫增彊劑聯閤抗生素預防老年噁性腫瘤術後感染的有效性及經濟性。方法：納入外科480例老年噁性腫瘤患者，併隨機分為甘露聚糖肽註射液組、胸腺五肽組、胸腺肽α1組和空白組各120例，均行外科腫瘤根治性手術。三箇治療組術前3天至術後一週應用免疫增彊劑，給藥方法為甘露聚糖肽註射液10～20mg/d，胸腺五肽2ml/d，胸腺肽α13.2mg/週，空白組則不予應用免疫增彊劑，術後均選用抗生素滴註，觀察兩組的呼吸道、泌尿繫統、切口感染及其他感染情況，併對4種藥物的治療方案行經濟學評價。結果：四組腫瘤患者呼吸道感染髮生率分彆為2.5%、3.34%、3.34%，14.16%；泌尿繫統感染髮生率分彆為3.34%，6.67%，5.83%，15%；切口感染髮生率分彆為2.5%，18.35%，17.5%，15%；總感染髮生率分彆為15%，19.16%，18.33%，48.33%，免疫增彊組術後感染的髮生率明顯低于空白組，其中甘露聚糖肽組預防切口感染率優勢更佳，且具有統計學差異（P＜0.05），甘露聚糖肽成本-效益是免疫增彊劑中最佳。結論：免疫增彊劑能降低老年噁性腫瘤患者術後感染髮生率，但上述三種免疫增彊劑在降低總感染髮生率上不具有統計學差異，甘露聚糖肽在降低切口感染方麵可能優于其他2種免疫增彊劑，藥物經濟學分析甘露聚糖肽更為經濟。
목적：비교3충상용면역증강제연합항생소예방노년악성종류술후감염적유효성급경제성。방법：납입외과480례노년악성종류환자，병수궤분위감로취당태주사액조、흉선오태조、흉선태α1조화공백조각120례，균행외과종류근치성수술。삼개치료조술전3천지술후일주응용면역증강제，급약방법위감로취당태주사액10～20mg/d，흉선오태2ml/d，흉선태α13.2mg/주，공백조칙불여응용면역증강제，술후균선용항생소적주，관찰량조적호흡도、비뇨계통、절구감염급기타감염정황，병대4충약물적치료방안행경제학평개。결과：사조종류환자호흡도감염발생솔분별위2.5%、3.34%、3.34%，14.16%；비뇨계통감염발생솔분별위3.34%，6.67%，5.83%，15%；절구감염발생솔분별위2.5%，18.35%，17.5%，15%；총감염발생솔분별위15%，19.16%，18.33%，48.33%，면역증강조술후감염적발생솔명현저우공백조，기중감로취당태조예방절구감염솔우세경가，차구유통계학차이（P＜0.05），감로취당태성본-효익시면역증강제중최가。결론：면역증강제능강저노년악성종류환자술후감염발생솔，단상술삼충면역증강제재강저총감염발생솔상불구유통계학차이，감로취당태재강저절구감염방면가능우우기타2충면역증강제，약물경제학분석감로취당태경위경제。
[ABSTRACT]Objective:To compare the effectiveness and economical efifciency of three common immunopotentiators with antibiotic on postoperative infection of elderly cancers. Methods: 480 elderly cancer patients hospitalized in the surgical oncology and geriatrics of XX center were randomly divided into mannatide injection group, thymopentin group, thymosin α1 group and blank group, with each 120 patients. Four groups underwent radical surgical tumor surgery. From preoperative 3 days to a week after surgery, three treatment groups were given with immunopotentiators, mannatide injection 10~20mg/d, thymopentin 2 ml/d, thymosin α1 3.2 mg/week, whereas blank group received no immunopotentiators. Each group was infused with postoperative antibiotics injection. Observe the infection of respiratory, urinary system, wound and other infection, and evaluate the economical efifciency of four kinds of therapy. Results:Incidences of respiratory infection in four groups were 2.5%, 3.34%, 3.34%, 14.16%. Incidences of urinary infection were 3.34%, 6.67%, 5.83%, 15%. Incidences of wound infection were 2.5%, 18.35%, 17.5%, 15%. Total incidences of infection were 15%, 19.16%, 18.33%, 48.33%. Incidences of postoperative infection in immune-enhancing groups were significantly lower than blank group. Particularly mannatide group worked better on prevention of wound infection, with signiifcant difference (P<0.05), and cost-efifciency of mannatide was the best. Conclusion: The immune enhancer can reduce the incidence of postoperative infections in elderly cancer patients, but these three immunopotentiators were not statistically different in reducing the total incidence of infection. Mannatide may be superior in reducing wound infections to other two kinds of immunopotentiators, and pharmacoeconomic analysis showed mannatide was more economical.
